Canada's Drug Agency Reports 10% Rise in Drug Submissions Despite 15% Drop in Approvals for 2024
核心洞察
Canada's Drug Agency (搜索) published comprehensive data showing drug submissions increased by 10% while approvals decreased by 15% in 2024 compared to the previous four years.
Oncology drugs (搜索) represented 32% of all drug submissions and 27% of approvals in 2024, with 43% of Health Technology Assessment recommendations issued for cancer (搜索) treatments.
The agency issued 93% of its 2024 HTA recommendations with clinical criteria and conditions for reimbursement, reflecting increasingly stringent evaluation standards.
Canada's Drug Agency (搜索) (CDA-AMC (搜索)) has released comprehensive data revealing significant shifts in the country's pharmaceutical landscape, with drug submissions rising 10% while approvals fell 15% in 2024 compared to the previous four-year period. The data, published as part of the Data Systems and Analytics program, provides unprecedented insight into regulatory trends affecting both oncology and non-oncology therapeutics from 2020-2024.
Diverging Trends in Submissions and Approvals
The newly released data, primarily sourced from Health Canada's Drug and Health Product Submissions Under Review list and CDA-AMC (搜索) reimbursement review reports, highlights a growing disconnect between industry submission activity and regulatory approval rates. Despite the increase in submissions, the 15% decline in approvals suggests heightened regulatory scrutiny or more complex evaluation processes.
Oncology drugs (搜索) continue to dominate the regulatory pipeline, accounting for 32% of drug submissions and 27% of approvals in 2024. This therapeutic area's prominence reflects ongoing industry focus on cancer (搜索) treatment innovation and the significant unmet medical needs in oncology.
Health Technology Assessment Activity Intensifies
The data reveals increased activity in Canada's Health Technology Assessment process, with HTA submissions rising 11% in 2024 compared to the past four years. Notably, 71% of HTA submissions were filed before Health Canada issued a notice of compliance, indicating pharmaceutical companies' proactive approach to reimbursement planning.
CDA-AMC (搜索) issued 10% more HTA recommendations in 2024 than in previous years, with 43% of these recommendations specifically addressing oncology drugs (搜索). This concentration underscores the agency's focus on evaluating cancer (搜索) therapeutics for public reimbursement.
Stringent Reimbursement Standards
A striking finding from the 2024 data shows that 93% of HTA recommendations were issued with clinical criteria and/or conditions for reimbursement. This high percentage indicates that CDA-AMC (搜索) is applying increasingly rigorous standards for drug access, requiring specific clinical parameters or usage conditions rather than providing unrestricted reimbursement approval.
Over the five-year period from 2020-2024, only 48.5% of new drug approvals were submitted for reimbursement review, suggesting that nearly half of approved drugs either target private markets or face barriers to public reimbursement consideration.
New Resource Clarifies Complex Pathways
On December 3, 2025, CDA-AMC (搜索) released "Drug Access in Canada: Understanding the System," a comprehensive resource designed to explain the multi-step process governing drug approval and reimbursement in Canada. The resource covers the complete pathway from clinical trials through regulatory review by Health Canada, HTA recommendations for public drug plan listings, drug pricing negotiations, formulary listings, and measures to prevent excessive pricing of patented medicines.
This educational initiative addresses the complexity of Canada's drug access system, which involves multiple stakeholders and evaluation stages before patients can access new therapeutics through public funding.